Paolo Mulatero

List of Publications by Citations

Source: https://exaly.com/author-pdf/5019460/paolo-mulatero-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137 papers	7,691 citations	43 h-index	86 g-index
139 ext. papers	9,369 ext. citations	6.1 avg, IF	5.63 L-index

#	Paper	IF	Citations
137	Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1045-50	5.6	745
136	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. *Nature Genetics*, **2013**, 45, 440-4, 444e1-2	36.3	375
135	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 689-699	18.1	355
134	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 41-50	18.1	324
133	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. *Journal of the American College of Cardiology*, **2017**, 69, 1811-1820	15.1	315
132	Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. *Hypertension*, **2002**, 40, 897-902	8.5	297
131	Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 454-9	5.6	292
130	Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 4826-33	5.6	273
129	Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. *Hypertension*, **2020**, 76, 366-372	8.5	216
128	Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. *Hypertension*, **2014**, 64, 354-61	8.5	211
127	Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. *Hypertension*, **2012**, 59, 592-8	8.5	206
126	Comparison of confirmatory tests for the diagnosis of primary aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2618-23	5.6	149
125	KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. *Hypertension*, **2012**, 59, 235-40	8.5	145
124	Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. *Hypertension*, **2014**, 63, 188-95	8.5	126
123	Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 1366-71	5.6	123
122	Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. *Hypertension*, **2010**, 55, 667-73	8.5	116
121	Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2573-5	5.6	116

120	Diagnosis of primary aldosteronism: from screening to subtype differentiation. *Trends in Endocrinology and Metabolism*, **2005**, 16, 114-9	8.8	112
119	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. *Molecular and Cellular Endocrinology*, **2015**, 411, 146-54	4.4	96
118	Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). *Hypertension*, **2011**, 58, 797-803	8.5	95
117	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 296-303	18.1	91
116	The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. *Endocrine Reviews*, **2018**, 39, 1057-1088	27.2	89
115	Role of KCNJ5 in familial and sporadic primary aldosteronism. *Nature Reviews Endocrinology*, **2013**, 9, 104-12	15.2	86
114	Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. *Journal of Hypertension*, **2016**, 34, 2253-7	1.9	85
113	18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 881-9	5.6	82
112	Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. *Clinical Chemistry*, **2007**, 53, 1968-71	5.5	82
111	SUN-LB97 Targeted Metabolomics as a Screening Tool in the Diagnosis of Endocrine Hypertension. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
110	Psychological assessment of primary aldosteronism: a controlled study. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E878-83	5.6	76
109	Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. *Hypertension*, **2012**, 59, 840-6	8.5	74
108	The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. *Nature Structural and Molecular Biology*, **1997**, 4, 32-5	17.6	74
107	Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. *Journal of Hypertension*, **2008**, 26, 1577-82	1.9	71
106	Diagnosis and treatment of low-renin hypertension. *Clinical Endocrinology*, **2007**, 67, 324-34	3.4	70
105	a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1861-5	5.6	65
104	CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. *Hypertension*, **2000**, 35, 694-8	8.5	61
103	Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 3187-91	5.6	57

102	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. *Hypertension*, **2018**, 72, 641-649	8.5	54
101	Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. *Hypertension*, **2012**, 59, 833-9	8.5	51
100	Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4158-66	5.6	50
99	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. *Journal of Hypertension*, **2016**, 34, 920-7	1.9	49
98	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. *Hypertension*, **2016**, 67, 146-52	8.5	48
97	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. *Hypertension*, **2018**, 71, 317-325	8.5	46
96	A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E114-8	5.6	44
95	Captopril test can give misleading results in patients with suspect primary aldosteronism. *Hypertension*, **2007**, 50, e26-7	8.5	44
94	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1919-1928	1.9	42
93	International Histopathology Consensus for Unilateral Primary Aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 42-54	5.6	42
92	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. *Molecular and Cellular Endocrinology*, **2015**, 399, 311-20	4.4	40
91	Liddle Syndrome: Review of the Literature and Description of a New Case. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	40
90	Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. *Journal of Hypertension*, **2011**, 29, 1773-7	1.9	40
89	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. *Annals of Surgery*, **2020**, 272, 1125-1132	7.8	40
88	Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. *Hypertension*, **2010**, 55, 1468-75	8.5	39
87	Differential diagnosis of primary aldosteronism subtypes. *Current Hypertension Reports*, **2009**, 11, 217-23	4.7	39
86	alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes. *Hypertension*, **1999**, 33, 708-12	8.5	39
85	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. *Hypertension*, **2018**, 72, 650-657	8.5	36

84	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. *Molecular and Cellular Endocrinology*, **2014**, 394, 13-20	4.4	36
83	GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. *European Journal of Endocrinology*, **2018**, 178, R101-R111	6.5	33
82	Mineralocorticoid receptor blockade in the protection of target organ damage. *Cardiovascular and Hematological Agents in Medicinal Chemistry*, **2006**, 4, 75-91	1.9	33
81	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. *High Blood Pressure and Cardiovascular Prevention*, **2020**, 27, 105-108	2.9	32
80	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. *Journal of Pharmaceutical and Biomedical Analysis*, **2016**, 129, 535-541	3.5	31
79	Is Primary Aldosteronism Still Largely Unrecognized?. *Hormone and Metabolic Research*, **2017**, 49, 908-914	2.1	30
78	Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3197-201	5.6	30
77	Diagnosis and treatment of primary aldosteronism. *Reviews in Endocrine and Metabolic Disorders*, **2011**, 12, 3-9	10.5	29
76	Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. *Kidney International*, **2005**, 67, 631-7	9.9	29
75	Is There a Role for Genomics in the Management of Hypertension?. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	28
74	Blood pressure in patients with primary aldosteronism is influenced by bradykinin B(2) receptor and alpha-adducin gene polymorphisms. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 3337-43	5.6	28
73	Renal damage in primary aldosteronism: a systematic review and meta-analysis. *Journal of Hypertension*, **2020**, 38, 3-12	1.9	27
72	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	25
71	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1929-1936	1.9	25
70	Diagnostic approach to low-renin hypertension. *Clinical Endocrinology*, **2018**, 89, 385-396	3.4	25
69	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. *Journal of Pharmaceutical and Biomedical Analysis*, **2017**, 142, 279-285	3.5	24
68	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. *Hypertension*, **2020**, 75, 1025-1033	8.5	24
67	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. *Pharmacogenomics*, **2014**, 15, 1643-52	2.6	24

66	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. *International Journal of Cardiology: Hypertension*, **2020**, 5, 100029	1.6	24
65	Genetics of primary aldosteronism. *Journal of Hypertension*, **2004**, 22, 663-70	1.9	22
64	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. *Journal of Steroid Biochemistry and Molecular Biology*, **2019**, 189, 274-282	5.1	22
63	The SPARTACUS Trial: Controversies and Unresolved Issues. *Hormone and Metabolic Research*, **2017**, 49, 936-942	3.1	21
62	QT interval in patients with primary aldosteronism and low-renin essential hypertension. *Journal of Hypertension*, **2006**, 24, 2459-64	1.9	21
61	Primary Aldosteronism and Obstructive Sleep Apnea: A Cross-Sectional Multi-Ethnic Study. *Hypertension*, **2019**, 74, 1532-1540	8.5	19
60	1,25-Dihydroxyvitamin D inhibits the human H295R cell proliferation by cell cycle arrest: a model for a protective role of vitamin D receptor against adrenocortical cancer. *Journal of Steroid Biochemistry and Molecular Biology*, **2014**, 140, 26-33	5.1	19
59	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	18
58	Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. *Endocrine Journal*, **2012**, 59, 497-502	2.9	18
57	Aldosterone effects on glomerular structure and function. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2015**, 16, 730-8	3	17
56	Evaluation of primary aldosteronism. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2010**, 17, 188-93	4	16
55	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	16
54	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. *JAMA Network Open*, **2020**, 3, e2016209	10.4	16
53	Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology. *Endocrinology*, **2017** , 158, 4129-4138	4.8	15
52	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. *Hypertension*, **2019**, 74, 359-367	8.5	15
51	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. *Endocrine*, **2017**, 58, 503-512	4	14
50	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. *Molecular and Cellular Endocrinology*, **2012**, 355, 162-8	4.4	14
49	Is familial hyperaldosteronism underdiagnosed in hypertensive children?. *Hypertension*, **2011**, 57, 1053-5	8.5	14

48	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree		14
47	Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. *Liver*, **1998**, 18, 420-6		13
46	A time-resolved fluoroimmunoassay for 18-oxocortisol and 18-hydroxycortisol. Development of a monoclonal antibody to 18-oxocortisol. *Journal of Steroid Biochemistry and Molecular Biology*, **2002**, 82, 83-8	5.1	13
45	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	11
44	Mutation affecting the conserved acidic WNK1 motif causes inherited hyperkalemic hyperchloremic acidosis. *Journal of Clinical Investigation*, **2020**, 130, 6379-6394	15.9	11
43	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. *Hypertension*, **2020**, 75, 163-172	8.5	10
42	Diagnosis and treatment of unilateral forms of primary aldosteronism. *Current Hypertension Reviews*, **2013**, 9, 156-65	2.3	9
41	10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. *Journal of Hypertension*, **2019**, 37, 603-611	1.9	9
40	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. *Hypertension Research*, **2020**, 43, 500-510	4.7	9
39	Adrenal Venous Sampling-Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e1400-e1407	5.6	9
38	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	8
37	Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtype-Specific Alterations. *Proteomics - Clinical Applications*, **2019**, 13, e1800049	3.1	8
36	Genetic and potential autoimmune triggers of primary aldosteronism. *Hypertension*, **2015**, 66, 248-53	8.5	7
35	Diagnosis and treatment of primary aldosteronism. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 876-892	18.1	7
34	Primary aldosteronism in the primary care setting. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2018**, 25, 155-159	4	6
33	Aldosterone as an independent factor in cerebrovascular damage. *Clinical and Experimental Hypertension*, **2008**, 30, 785-97	2.2	6
32	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 1111-1128	5.6	6
31	The spectrum of low-renin hypertension. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2020**, 34, 101399	6.5	5

30	Hypertension, genotype and oral contraceptives. *Pharmacogenomics*, **2002**, 3, 57-63	2.6	5
29	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. *Hypertension*, **2021**, 78, 726-737	8.5	5
28	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E1262-9	5.6	4
27	Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?. *Hormone and Metabolic Research*, **2020**, 52, 366-372	3.1	4
26	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e1708-e1716	5.6	4
25	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e3655-e3664	5.6	4
24	Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
23	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. *Journal of the Endocrine Society*, **2017**, 1, 401-406	0.4	3
22	Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. *Hypertension*, **2021**, 77, 1647-1658	8.5	3
21	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. *High Blood Pressure and Cardiovascular Prevention*, **2016**, 23, 203-8	2.9	3
20	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. *Journal of Pharmacological and Toxicological Methods*, **2018**, 94, 29-35	1.7	3
19	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature.. *Translational Research*, **2022**,	11	3
18	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. *Endocrine*, **2016**, 54, 826-829	4	2
17	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. *European Journal of Endocrinology*, **2020**, 183, 657-667	6.5	2
16	Primary Aldosteronism in the Elderly. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	2
15	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. *Hypertension*, **2016**, 67, e3-4	8.5	1
14	Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. *High Blood Pressure and Cardiovascular Prevention*, **2008**, 15, 121-125	2.9	1
13	Ca2+ channels of the L-type in peripheral blood lymphocytes of essential hypertensives. *American Journal of Hypertension*, **1999**, 12, 40-6	2.3	1

List of Publications

12	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. *European Heart Journal Supplements*, **2020**, 22, H70-H73	1.5	1
11	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. *European Heart Journal Supplements*, **2021**, 23, B77-B81	1.5	1
10	Quality of life in primary aldosteronism: A prospective observational study. *European Journal of Clinical Investigation*, **2021**, 51, e13419	4.6	1
9	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey.. *High Blood Pressure and Cardiovascular Prevention*, **2022**,	2.9	1
8	Primary aldosteronism in pregnancy.. *Reviews in Endocrine and Metabolic Disorders*, **2022**, 1	10.5	1
7	Genetics of Familial Hyperaldosteronism **2019**, 623-630		0
6	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. *Hypertension*, **2021**, 78, 1595-1604	8.5	0
5	Issues in the Diagnosis and Treatment of Primary Aldosteronism. *High Blood Pressure and Cardiovascular Prevention*, **2016**, 23, 73-82	2.9	
4	The Renin-Angiotensin System, Capri 2005. *High Blood Pressure and Cardiovascular Prevention*, **2005**, 12, 91-108	2.9	
3	Controversies on the Diagnosis of Primary Aldosteronism. *High Blood Pressure and Cardiovascular Prevention*, **2006**, 13, 173-178	2.9	
2	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. *Frontiers in Pharmacology*, **2021**, 12, 668843	5.6	
1	L□peraldosteronismo primitivo: dalla genetica alla terapia. *L Endocrinologo*, **2016**, 17, 90-96	0	